TP53 and central nervous system cancer: When the expression levels of MDM2 were reduced, albeit with different efficiencies, by the introduction of two siRNAs targeting distinct sequences within human MDM2, increases in the expression level of p53 were greater in glioma stem cells than in their non-stem cell counterparts (Figure 2A).